Cue Biopharma Inc (NAS:CUE)
$ 1.72 -0.06 (-3.37%) Market Cap: 103.56 Mil Enterprise Value: 84.79 Mil PE Ratio: 0 PB Ratio: 3.87 GF Score: 64/100

Q4 2019 Cue Biopharma Inc Earnings Call Transcript

Mar 17, 2020 / 08:30PM GMT
Release Date Price: $11.41 (-2.14%)
Operator

Greetings, and welcome to the Cue Biopharma Fourth Quarter and Fiscal Year 2019 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Ashley Robinson of Investor Relations. Thank you. You may begin.

Ashley R. Robinson
LifeSci Advisors, LLC - MD

Thanks, Diego, and good afternoon, everyone. Thank you for joining us on today's investor and analyst update call. Joining me on the call today are Dan Passeri, Cue Biopharma's CEO; Dr. Anish Suri, President and Chief Scientific Officer; Dr. Ken Pienta, Acting Chief Medical Officer; and Kerri-Ann Millar, Vice President of Finance and Principal Accounting and Finance Officer.

Before we begin, I would like to remind you that during today's call, the company will be making forward-looking statements. Various remarks that the company makes during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot